$ 722.01
Key Takeaways
Risk factor
Very vulnerable to price shocks
Profitability factor
Favourable analyst view
About
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of ARGX is 849 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
